(IN BRIEF) Sanofi has secured regulatory approval in China for two innovative medicines, Myqorzo for obstructive hypertrophic cardiomyopathy and Redemplo for familial chylomicronemia syndrome. The approvals expand treatment options for patients with serious cardiovascular and rare metabolic diseases and underscore … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged aficamten, cardiovascular disease, China NMPA, clinical phase 3 trials, familial chylomicronemia syndrome, FCS, Greater China, innovative medicines, Myqorzo, obstructive hypertrophic cardiomyopathy, oHCM, Olivier Charmeil, plozasiran, rare diseases, Redemplo, Sanofi, Sanofi Strengthens China Portfolio with Approval of Two Innovative Therapies for oHCM and FCS, siRNA therapy
(IN BRIEF) The European Commission, EMA, and HMA have set new targets to strengthen Europe’s role in clinical research by authorising an additional 500 multinational clinical trials over five years and ensuring that two-thirds of studies begin patient recruitment within … Read the full press release
Posted in European Union, Government, Healthcare, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged ACT EU, Ana Zanoletty, clinical trial ecosystem, Clinical Trials Information System, Clinical Trials Regulation, COMBINE programme, Corinna Hartung, CTIS, CTR, CTR Collaborate, EMA, EMA and partners unveil new clinical trial benchmarks under ACT EU to enhance Europe’s competitiveness in medical research, EU healthcare, EU launches five-year plan to authorise 500 more multinational clinical trials and speed up patient recruitment timelines, Europe competitiveness, European Commission, Heads of Medicines Agencies, HMA, ICH E6 R3, innovative medicines, Marianne Lunzer, MedEthicsEU, medical research, multinational clinical trials, Patient Recruitment
Novartis announces that researchers can now request access to patient level data on newly approved innovative medicines in the United States and EU in 2014 through the Idea Point portal, and is committed to enhancing Clinical Study Report summaries for … Read the full press release
Posted in Healthcare, Management, Pharma & Biotech, Science, Switzerland
Tagged Clinical Study Reports, clinical trial data transparency, ClinicalTrials.gov, data transparency, innovative medicines, Novartis, Tim Wright, voluntarily disclosing summaries, voluntarily disclosing summaries of Clinical Study Reports
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?